EMATOLOGIA

GIUGNO 2026

LYMPHOMAS
Prof. Umberto Vitolo
Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italia
DLBCL: hot topics e le prospettive future
Prof. Stefano Luminari
USL-IRCCS di Reggio Emilia, UniMORE, Università Modena e Reggio Emilia, Modena, Italia
PERIPHERAL PROTEOMIC SIGNATURES ASSOCIATED WITH CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) TREATED WITH ODRONEXTAMAB PHASE 3 INMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS RECEIVING SECOND-LINE OUTCOMES AND PROGNOSTIC RISK FACTORS IN NODAL PERIPHERAL T-CELL LYMPHOMA. RESULTS FROM THE INTERNATIONAL T-CELL PROJECT 2.0 PROSPECTIVE COHORT STUDY
Prof.ssa Federica Cavallo
Università di Torino, Torino, Italia
FIRST-LINE ODRONEXTAMAB PLUS CHOP IN DIFFUSE LARGE B-CELL LYMPHOMA: OLYMPIA-3 PART 1B RESULTS
MM-AMYLOIDOSIS
Prof.ssa Elena Zamagni
Università di Bologna, IRCCS Policlinico Sant’Orsola, Bologna, Italia
EHA 2026: hot topics nel mieloma multiplo e amiloidosi
Prof. Claudio Cerchione
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST - IRCCS) “Dino Amadori”, Meldola (FC), Italia
COMPARATIVE EFFICACY OF LINVOSELTAMAB VERSUS TECLISTAMAB IN TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED MATCHING-ADJUSTED INDIRECT COMPARISON WITH LONGER FOLLOW-UP REAL-WORLD OUTCOMES IN SMOLDERING MULTIPLE MYELOMA IN EUROPE: FIRST RESULTS FROM THE SPARK STUDY Il mieloma multiplo: stato dell’arte e prospettive future
Prof. Paolo Milani
Università di Pavia, Pavia, Italia
INITIAL EFFICACY AND SAFETY DATA FROM THE PHASE 1/2 LINKER-AL2 STUDY OF LINVOSELTAMAB (LINVO) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS
CML
Prof. Giantonio Rosti
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola (FC), Italia
ASCIMINIB VERSUS SECOND-GENERATION TKIS IN CHRONIC-PHASE CML AFTER ≥2 PRIOR TKIS: A PROPENSITY SCORE-MATCHED ANALYSIS
Dott. Gianni Binotto
Università di Padova, Padova, Italia
ASC4FIRST WK 144 ANALYSIS: CONTINUED SUPERIOR EFFICACY AND FAVORABLE SAFETY OF ASCIMINIB VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Dott. Alessandro Costa
Ospedale Oncologico "A. Businco" ARNAS G. Brotzu, Cagliari, Italia
ASCIMINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INTERIM RESULTS FROM A PHASE II TRIAL FRONTLINE ASCIMINIB FOR CHRONIC PHASE CML: LONG TERM SAFETY AND EFFICACY IN THE ALLG CM13 ASCEND TRIAL
Prof. Mario Tiribelli
Università di Udine, Udine, Italia
RISK OF PERMANENT FRONTLINE DISCONTINUATION DURING THE FIRST 36 MONTHS OF THERAPY WITH TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA: A “CAMPUS CML” STUDY WITH A NEW “AD HOC” SCORE PROPOSAL
Prof.ssa Esther N. Oliva
University Healthcare NHS Trust, Brunel University, London, UK
EMOTIONAL DISTRESS DOMINATES QUALITY OF LIFE BURDEN IN CML: PSYCHOMETRIC VALIDATION OF PATIENT REPORTED OUTCOMES IN A GLOBAL LEUKEMIA EXPERIENCE SURVEY
Dott.ssa Mariella D’Adda
ASST Spedali Civili, Brescia, ERN/EuroBloodNet, Brescia, Italia
HOW MANY CHRONIC-PHASE CML PATIENTS STARTING TYROSINE KINASE INHIBITORS CAN ACHIEVE A PERSISTENT TREATMENT FREE REMISSION AND BE POTENTIALLY CURED? A SINGLE CENTER REAL-LIFE EXPERIENCE.
ITP
Dott.ssa Monica Carpenedo
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italia
EFFECTS OF IANALUMAB TREATMENT ON B CELL ACTIVATION, MATURATION, AND MAINTENANCE OF VACCINE TITERS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN THE PHASE 2 VAYHIT3 STUDY
Prof.ssa Elena Rossi
Università Cattolica del Sacro Cuore, Roma, Italia
EFFECT OF IANALUMAB PLUS ELTROMBOPAG ON PATIENT-REPORTED OUTCOMES IN PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS FROM THE VAYHIT2 PHASE 3 TRIAL
MPN
Dott.ssa Barbara Mora
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italia
Overview simposio “Therapeutic Advances in Myelofibrosis: emerging classes and combination strategies”
Dott. Alessandro Lucchesi
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola (FC), Italia
EVALUATION OF PELABRESIB (PELA) AS ADD-ON THERAPY TO JANUS KINASE INHIBITOR (JAKI) RUXOLITINIB (RUX) IN MYELOFIBROSIS (MF) PATIENTS: RESULTS FROM ARM 2 OF THE OPEN-LABEL, PHASE 2 MANIFEST STUDY Overview sessione “Identification of biomarkers to product disease progression via molecular analysis of patients with low risk myelofibrosis”
Prof. Mario Tiribelli
Università di Udine, Udine, Italia
PELABRESIB MONOTHERAPY IN MYELOFIBROSIS AFTER JANUS KINASE INHIBITOR FAILURE: RESULTS FROM ARM 1 OF THE OPEN-LABEL, PHASE 2 MANIFEST STUDY
Dott. Andrea Patriarca
AOU Maggiore della Carità-Novara, Novara, Italia
PELABRESIB MONOTHERAPY IN MYELOFIBROSIS AFTER JANUS KINASE INHIBITOR FAILURE: RESULTS FROM ARM 1 OF THE OPEN-LABEL, PHASE 2 MANIFEST STUDY
PNH
Dott. Bruno Fattizzo
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italia
IPTACOPAN DEMONSTRATES SUSTAINED EFFICACY AND SAFETY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UP TO 4 YEARS OF FOLLOW-UP IN PATIENTS FROM APPLY, APPOINT AND ROLL-OVER EXTENSION PROGRAM
Dott.ssa Sarah Marktel
Ospedale San Raffaele, Milano, Italia
IPTACOPAN DEMONSTRATES SUSTAINED EFFICACY AND SAFETY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UP TO 4 YEARS OF FOLLOW-UP IN PATIENTS FROM APPLY, APPOINT AND ROLL-OVER EXTENSION PROGRAM LONG-TERM SAFETY WITH IPTACOPAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): POOLED ANALYSIS OF DATA FROM PHASE 2 AND 3 STUDIES AND THE ROLL-OVER EXTENSION PROGRAM Overview sessione “From evidence to experience: Real-world insights into proximal complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH)
Prof.ssa Esther N. Oliva
University Healthcare NHS Trust, Brunel University, London, UK
BURDEN E UNMET NEEDS NELLA PNH: STATO DELL’ARTE E PROSPETTIVE FUTURE

DICEMBRE 2025

CML
Prof. Fausto Castagnetti
Istituto di Ematologia "L. e A. Seràgnoli", Università di Bologna, Bologna, Italia
Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study
Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial
Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis
Prof. Mario Tiribelli 
Università di Udine, Udine, Italia
Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)
Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP);
Dott.ssa Elisabetta Abruzzese
Ospedale Sant’Eugenio, ASL Roma 2, Italia
Asciminib and pregnancy in CML: Preliminary human data and clinical implications from 47 reported outcomes
ITP
Prof.ssa Elena Rossi
Università Cattolica del Sacro Cuore, Roma, Italia
Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmen
Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy
MPN
Prof. Alessandro Maria Vannucchi 
Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Firenze, Italia
Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF)
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study
Prof.ssa Paola Guglielmelli
Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Firenze, Italia
Clonal architecture inferred from routine NGS data predicts outcome and response to JAK-inhibitors in myelofibrosis
Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics
DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis
Prof. Massimiliano Bonifacio
Università di Verona, Policlinico G. B. Rossi, AOUI Verona, Italia
Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database
It’s not yet time to abandon ruxolitinib in anemic myelofibrosis: Predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib
Dott. Alessandro Lucchesi
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola (FC), Italia
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study
Dott.ssa Elisabetta Abruzzese
Ospedale Sant’Eugenio, ASL Roma 2, Italia
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study
NHL
Prof.ssa Simona Sica
Università Cattolica Sacro Cuore, Roma, Italia
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
Dott.ssa Beatrice Casadei
IRCSS Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola, Istituto di Ematologia “L. e A. Seràgnoli, Bologna, Italia
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results
Prof. Stefano Luminari
UNIMORE, Università degli Studi di Modena e Reggio Emilia, Italia
Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL)
Dott. Fabio Efficace
Health Outcomes Research Unit, Chair Working Party Quality of Life, Fondazione GIMEMA, Roma, Italia
Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: results from a prospective observational study
The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy
PNH
Prof.ssa Simona Sica
Università Cattolica Sacro Cuore, Roma, Italia
Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program
The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program
Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy
CLL
Prof. Antonio Cuneo 
Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Università di Ferrara, Italia
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients
Prof. Gianluca Gaidano
Università del Piemonte Orientale, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italia
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Prof. Paolo Ghia 
Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milano, Italia
Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies
Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study withmore than 5 years follow-up
Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study
MCL
Prof. Pier Luigi Zinzani
Istituto di Ematologia "L. e A. Seràgnoli", Università di Bologna, Bologna, Italia
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

GIUGNO 2025

CML
Prof.ssa Sara Galimberti
Università di Pisa,
Pisa, Italia
ASCIMINIB (ASC) SHOWS SUPERIOR TOLERABILITY VS NILOTINIB (NIL) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): PRIMARY ENDPOINT RESULTS OF THE PHASE (PH) 3B ASC4START TRIAL
Prof. Massimiliano Bonifacio
Università di Verona, Policlinico G. B. Rossi, AOUI Verona,
Verona, Italia
IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH ASCIMINIB (ASC) VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS (IS-TKIS) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): ASC4FIRST WK 48 ANALYSIS
Prof. Fausto Castagnetti
Istituto di Ematologia "L. e A. Seràgnoli", Università di Bologna,
Bologna, Italia
INTERIM ANALYSIS (IA) RESULTS FROM ASC2ESCALATE SUPPORT ASCIMINIB (ASC) AS A TREATMENT (TX) OPTION IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) AFTER 1 TYROSINE KINASE INHIBITOR (TKI)
FIRST-IN-HUMAN STUDY OF ASCIMINIB (ASC) MONOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
Dott. Gianni Binotto
Università di Padova,
Padova, Italia
ASC4OPT STUDY: HIGH EFFICACY AND FAVORABLE TOLERABILITY OF ASCIMINIB ONCE OR TWICE DAILY IN CML PATIENTS WITH SUBOPTIMAL RESPONSE, RESISTANCE OR INTOLERANCE OF 2 OR MORE TYROSINE KINASE INHIBITORS
FL
Prof. Alessandro Rambaldi
ASST Papa Giovanni XXIII,
Bergamo, Italia
RAPCABTAGENE AUTOLEUCEL (YTB323) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE II TRIAL CLINICAL UPDATE 
4-YEAR UPDATE OF PHASE 2 ELARA TRIAL: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) 
Prof.ssa Simona Sica
Università Cattolica Sacro Cuore,
Roma, Italia
RAPCABTAGENE AUTOLEUCEL (YTB323) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE II TRIAL CLINICAL UPDATE 
TISAGENLECLEUCEL VERSUS MOSUNETUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: AN UPDATED MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) ANALYSIS AFTER 3-YEAR FOLLOW-UP DATA
Dott.ssa Stefania Bramanti
IRCCS Humanitas Research Hospital,
Rozzano (MI), Italia
4-YEAR UPDATE OF PHASE 2 ELARA TRIAL: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) 
ITP
Dott.ssa Monica Carpenedo
ASST Grande Ospedale Metropolitano Niguarda,
Milano, Italia
A PHASE 2 STUDY OF IANALUMAB IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH AT LEAST TWO LINES OF THERAPY (VAYHIT3)
Prof.ssa Elena Rossi
Università Cattolica del Sacro Cuore,
Roma, Italia
IANALUMAB' S DUAL MECHANISM OF ACTION: TARGETING B CELLS THROUGH ENHANCED B-CELL DEPLETION AND BLOCKADE OF B CELL-ACTIVATING FACTOR RECEPTOR SIGNALING
A PHASE 2 STUDY OF IANALUMAB IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH AT LEAST TWO LINES OF THERAPY (VAYHIT3)
Dott. Giuseppe Carli
ULSS 8 Berica,
Vicenza, Italia
RETROSPECTIVE REVIEW OF COMPLIANCE WITH INTERNATIONAL GUIDELINES FOR IMMUNE THROMBOCYTOPENIA (ITP): STRATEGIES FOR IMPROVING DIAGNOSTIC AND THERAPEUTIC APPROACHES
MPN
Prof. Alessandro Maria Vannucchi
Azienda Ospedaliera Universitaria Careggi, Università di Firenze,
Firenze, Italia
PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III MANIFEST-2 STUDY
OVERVIEW SESSIONE "NAVIGATING POLYCYTHEMIA VERA (PV) AND MYELOFIBROSIS (MF) MANAGEMENT: TAILORING CARE FOR BETTER OUTCOMES"
Prof. Francesco Passamonti
Università degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda,
Milano, Italia
OVERVIEW SESSIONE "INNOVATIVE TREATMENT APPROACHES IN MPN"
Prof.ssa Paola Guglielmelli
Azienda Ospedaliera Universitaria Careggi, Università di Firenze,
Firenze, Italia
CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB AND ANEMIA SUPPORTING MEDICATIONS
PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III MANIFEST-2 STUDY
A DELPHI CONSENSUS TO DEFINE DISEASE PROGRESSION AND DISEASE MODIFICATION IN POLYCYTHEMIA VERA
Dott.ssa Alessandra Iurlo
IRCCS Fondazione Ca' Granda Policlinico di Milano
HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PRE-FIBROTIC AND OVERT MYELOFIBROSIS COMPARED TO THE GENERAL POPULATION AND PHYSICIAN PERCEPTIONS: RESULTS FROM THE GIMEMA-PROPHECY STUDY
CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB AND ANEMIA SUPPORTING MEDICATIONS
IMPACT OF ELN CLINICAL SIGNS AND SYMPTOMS ON OUTCOMES IN POLYCYTHEMIA VERA PATIENTS TREATED WITH HYDROXYUREA OR RUXOLITINIB: A COOPERATIVE STUDY
Dott.ssa Barbara Mora
Fondazione I.R.C.C.S. Ca' Granda Ospedale Maggiore Policlinico,
Milano, Italia
GENOMIC PROFILING FOR CLINICAL DECISION MAKING IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Prof. Giovanni Caocci
Ospedale "A. Businco", ARNAS "G. Brotzu", Università degli Studi di Cagliari,
Cagliari, Italia
HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PRE-FIBROTIC AND OVERT MYELOFIBROSIS COMPARED TO THE GENERAL POPULATION AND PHYSICIAN PERCEPTIONS: RESULTS FROM THE GIMEMA-PROPHECY STUDY
Dott. Roberto Latagliata
Unità Operativa Complessa, ASL Viterbo,
Viterbo, Italia
CLINICAL PATHWAYS AND PROGNOSTIC STRATEGIES IN MYELOFIBROSIS: A REAL-WORLD ANALYSIS OF GERMAN PRACTICE
EFFECT OF THERAPEUTICALLY TARGETING BET BROMODOMAINS IN ENHANCING MARKERS OF MACROPHAGE PHAGOCYTOSIS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY FOR MPN
Dott.ssa Novella Pugliese
Policlinico Universitario Federico II, Università di Napoli Federico II,
Napoli, Italia
CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB AND ANEMIA SUPPORTING MEDICATIONS
RETROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS TREATED WITH RUXOLITINIB: JUMP STUDY
USE OF RUXOLITINIB AS SECOND-LINE TREATMENT IN PATIENTS WITH POLYCYTHAEMIA VERA: A MULTICENTRE STUDY
Dott. Andrea Duminuco
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, A.O.U. Policlinico "G. Rodolico-San Marco",
Catania, Italia
LYMPHOCYTE TO MONOCYTE RATIO MAY PREDICT TRANSFORMATION TO MYELOFIBROSIS FOR POLYCYTHEMIA VERA PATIENTS TREATED WITH RUXOLITINIB: EXPERIENCE FROM MAJIC-PV TRIAL
PNH
Prof.ssa Simona Sica
Università Cattolica Sacro Cuore,
Roma, Italia
THE 2-YEAR SAFETY AND EFFICACY OF IPTACOPAN MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) FROM APPLY- AND APPOINT-PNH STUDIES WHO ENTERED THE ROLL-OVER EXTENSION PROGRAM (REP)
Dott. Francesco Versino
IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Università statale di Milano,
Milano, Italia
EFFECTIVENESS AND SAFETY OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH PERSISTENT ANEMIA AFTER C5 INHIBITION: THE REAL-WORLD EXPERIENCE OF THE FRENCH EARLY ACCESS PROGRAM
PROPHYLAXIS AND MANAGEMENT OF THROMBOEMBOLISM IN PNH PATIENTS: AN ITALIAN SURVEY
REAL-WORLD OUTCOMES AND CLINICAL BURDEN OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

DICEMBRE 2024

CML
Prof. Fausto Castagnetti
Istitituto di Ematologia "L. e A. Seràgnoli", Università di Bologna, Bologna, Italia
Asciminib in prima linea
- Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
- Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Asciminib nelle linee successive
- Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
- ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs
FL
Prof. Simone Ferrero
Università di Torino, Ematologia Universitaria. AOU "Città della Salute e della Scienza, Torino, Italia
- Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
- A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
Dott.ssa Beatrice Casadei
IRCSS Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola, Istituto di Ematologia “L. e A. Seràgnoli, Bologna
- A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
Prof. Stefano Luminari
UniMORE, Università di Modena e Reggio Emilia, Modena, Italia
- Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
Prof.ssa Simona Sica
Università Cattolica Sacro Cuore, Roma, Italia
- Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
GVHD
Prof. Alessandro Rambaldi
ASST Papa Giovanni XXIII, Bergamo, Italia
- Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk GvHD
- Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States
Prof. Emanuele Angelucci
IRCCS Ospedale Policlinico San Martino, Genova, Italia
- Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
Prof. Nicola Polverelli
Fondazione IRCCS Policlinico San Matteo, Pavia, Italia
- Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
- Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States
ITP
Prof.ssa Elena Rossi
Università Cattolica del Sacro Cuore, Roma, Italia
- Ianalumab, an ADCC-Enhanced Anti-BAFF-Receptor Antibody, Has Beneficial Effects in an Active Mouse Model of Immune Thrombocytopenia (ITP)
Prof. Francesco Zaja
ASUGI, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italia
- A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
MPN
Prof. Francesco Passamonti
Università degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda, Milano, Italia
- Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
- Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal
- Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications
Dott.ssa Barbara Mora
Fondazione I.R.C.C.S. Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italia
- Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
- Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients
Prof. Alessandro Maria Vannucchi
Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Firenze, Italia
- Lo stato dell’arte e prospettive per il paziente con PV
Prof.ssa Paola Guglielmelli
Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Firenze, Italia
- Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
- Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

GIUGNO 2024

CML
Prof. Fausto Castagnetti
Istitituto di Ematologia "L. e A. Seràgnoli", Università di Bologna,
Bologna, Italia
Asciminib (asc) provides superior efficacy and excellent safety and tolerability vs tyrosine kinase inhibitors (tki) in newly diagnosed chronic myeloid leukemia (cml) in the pivotal asc4first study
Overview sessione “beyond responses: optimizing outcomes from the start of the chronic myeloid leukemia treatment journey”
Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (alertcml)
Prof.ssa Carmen Fava
Università di Torino,
Torino, Italia
Propensity score matching analysis comparing asciminib versus ponatinib for its treatment outomes in chronic myeloid leukemia patients
Dott.ssa Cristina Bucelli
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico,
Milano, Italia
Treatment patterns and real-world clinical outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib in oncology practices in the united states
Asc4real: efficacy and tolerability comparison between ascembl study, a phase 3 randomized clinical trial (rct), and real-world (rw) experience with asciminib in cml patients beyond 2 tkis
Dott.ssa Mariella D’Adda
Azienda Ospedaliera Spedali Civili,
Brescia, Italia
Second tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia-chronic phase patients: single center real-life experience
FL
Prof. Massimo Martino
Presidente GITMO, Centro Trapianti Midollo Osseo, Azienda Ospedaliera BMM,
Reggio Calabria, Italia
Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up
Comparable outcomes of cd19-targeting car-t therapy in transformed follicular lymphoma and de novo diffuse large bcell lymphoma
Prof. Stefano Luminari
UniMORE, Università di Modena e Reggio Emilia,
Modena, Italia
Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up
Long-term durable responses in patients with r/r all, dlbcl, and fl treated with tisagenlecleucel and its association with persistence of chimeric antigen receptor (car) t-cells
Comparable outcomes of cd19-targeting car-t therapy in transformed follicular lymphoma and de novo diffuse large bcell lymphoma
GVHD
Prof. Massimo Martino
Presidente GITMO, Centro Trapianti Midollo Osseo, Azienda Ospedaliera BMM,
Reggio Calabria, Italia
Update sulle nuove line guida
Prof. Alessandro Rambaldi
ASST Papa Giovanni XXIII,
Bergamo, Italia
Gvhd: lo stato dell’arte
ITP-PNH
Dott. Bruno Fattizzo
Dott. Bruno Fattizzo Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milano, Italia
ITP
Clonal hematopoiesis in patients with immune thrombocytopenia: an international multicenter study
Dott. Bruno Fattizzo
Dott. Bruno Fattizzo Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milano, Italia
PNH
Effects of oral iptacopan monotherapy, including increased paroxysmal nocturnal hemoglobinuria red blood cell clone size, are maintained in complement inhibitor-naïve patients: final appoint-pnh data

Effects of oral iptacopan monotherapy, including increased paroxysmal nocturnal hemoglobinuria red blood cell clone size, are sustained in anti-c5-treated patients with anemia: final apply-pnh data
Breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors: a multicenter international study
Prof.ssa Elena Rossi
Università Cattolica del Sacro Cuore,
Roma, Italia
ITP
Prolonged response after tpo-ra discontinuation in primary itp: long term follow-up of the stopago study, a prospective multicenter study
MPN
Prof. Alessandro Maria Vannucchi
Azienda Ospedaliera Universitaria Careggi, Università di Firenze,
Firenze, Italia
Ruxolitinib treatment in patients with polycythemia vera reduces jak2 allele burden and improves hematocrit control and symptom burden
Prognostic potential of inflammatory biomarkers in patients with polycythemia vera receiving ruxolitinib: an exploratory analysis of response, response-2, and pv-nis
Deciphering the predictors of death in polycythemia vera: focus on the neutrophil to lymphocyte ratio (nlr) and the incidence of arterial thrombosis
Prof. Giuseppe Palumbo
Università degli Studi di Catania, Policlinico G. Rodolico San Marco,
Catania, Italia
Intermediate-1 risk myelofibrosis patients treated with ruxolitinib: predictors of response and outcome may drive transplant decision
The impact of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib: results from the expanded-access jump study
Ruxolitinib starting dose reduction affect overall survival in myelofibrosis: aifa monitoring registries analysis
Prof. Francesco Passamonti
Università degli Studi di Milano, IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation,
Milano, Italia
Ruxolitinib treatment in patients with polycythemia vera reduces jak2 allele burden and improves hematocrit control and symptom burden
Overview sessione “multidisciplinary approach to mpn”
Prof.ssa Paola Guglielmelli
Azienda Ospedaliera Universitaria Careggi, Università di Firenze,
Firenze, Italia
Overview sessione “managing high-risk polycythemia vera: time to throw out the lifeline”